Patients who received concomitant NeP medications showed little difference in therapeutic response in comparison to those who received pregabalin alone.
Significant improvement were observed for sensitivity, depression, and anxiety, among others.
Patients with fibromyalgia had a high prevalence of TRAb positivity compared with control populations in previous studies.
Recent findings offer a new avenue for the development of peripheral analgesics with minimal adverse effects.
Patients with cancer or an autoimmune disease who underwent surgery were at a greater risk.
Diabetes, waist circumference, and prediabetes were the main metabolic factors associated with neuropathy.
Even after loss of exclusivity, pregabalin has lower health care costs than gabapentin.
The group developed the algorithm through a year-long process of reviewing relevant published data.
The small study documented several cases of denervation and increased thermal thresholds in patients treated with LCIG.
The designation has been granted to potentially treat neuropathic pain associated with diabetic peripheral neuropathy.
Neurology Advisor Articles
- Cannabis: Current Evidence and Research Recommendations
- Addressing Gender Differences in Concussion Diagnosis and Treatment
- Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
- Maternal Antiepileptic Use and Risk for Major Congenital Malformations in Offspring
- In Stroke, No Clear Benefit for Head Positioning